Publisher Improvement: Allogeneic CD5-specific CAR-T therapy for relapsed\/refractory T-ALL: a stage 1 trial

.Attribute Medication, Released online: 16 October 2024 doi:10.1038/ s41591-024-03348-1Publisher Modification: Allogeneic CD5-specific CAR-T treatment for relapsed/refractory T-ALL: a period 1 trial.